Cargando…

Reply to letter: Suicide in Parkinson's disease patients treated with levodopa‐carbidopa Intestinal Gel

Detalles Bibliográficos
Autores principales:	Fernandez, Hubert H., Standaert, David G., Chatamra, Krai, Benesh, Janet A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2015
Materias:	Letters: Published Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5034823/ https://www.ncbi.nlm.nih.gov/pubmed/26179940 http://dx.doi.org/10.1002/mds.26316

Ejemplares similares

Effect of levodopa-carbidopa intestinal gel on resting tremors in patients with advanced Parkinson’s disease
por: Fernandez, Hubert H, et al.
Publicado: (2016)

Effect of levodopa‐carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients
por: Antonini, Angelo, et al.
Publicado: (2016)

Effect of Levodopa‐carbidopa Intestinal Gel on Non‐motor Symptoms in Patients with Advanced Parkinson's Disease
por: Standaert, David G., et al.
Publicado: (2017)

Jejunal Infusion of Levodopa–Carbidopa Intestinal Gel Versus Oral Administration of Levodopa–Carbidopa Tablets in Japanese Subjects with Advanced Parkinson’s Disease: Pharmacokinetics and Pilot Efficacy and Safety
por: Othman, Ahmed A., et al.
Publicado: (2015)

Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa
por: Othman, Ahmed A., et al.
Publicado: (2017)

Systematic evaluation of levodopa-carbidopa intestinal gel patient-responder characteristics
por: Standaert, David G., et al.
Publicado: (2018)

Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson'd Disease: Final 12-Month, Open-Label Results
por: Fernandez, Hubert H, et al.
Publicado: (2015)

Efficacy and safety of levodopa–carbidopa intestinal gel from a study in Japanese, Taiwanese, and Korean advanced Parkinson’s disease patients
por: Murata, Miho, et al.
Publicado: (2016)

Integrated safety of levodopa‐carbidopa intestinal gel from prospective clinical trials
por: Lang, Anthony E., et al.
Publicado: (2015)

Safety and efficacy of levodopa-carbidopa intestinal gel: results from an open-label extension study in Japanese, Korean and Taiwanese patients with advanced Parkinson’s disease
por: Murata, Miho, et al.
Publicado: (2018)

Implementing Levodopa‐Carbidopa Intestinal Gel for Parkinson Disease: Insights from US Practitioners
por: Burack, Michelle, et al.
Publicado: (2018)

Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson's Disease Receiving ≥2000 mg Daily Dose of Levodopa
por: Zadikoff, Cindy, et al.
Publicado: (2020)

Levodopa‐carbidopa intestinal gel high concentration formulation is clinically bioequivalent to commercial formulation
por: Rosebraugh, Matthew, et al.
Publicado: (2019)

Polyneuropathy monitoring in Parkinson's disease patients treated with levodopa/carbidopa intestinal gel
por: Pauls, K. Amande M., et al.
Publicado: (2021)

Outcomes Impacting Quality of Life in Advanced Parkinson’s Disease Patients Treated with Levodopa-Carbidopa Intestinal Gel
por: Kovács, Norbert, et al.
Publicado: (2022)

Levodopa Carbidopa Intestinal Gel in Advanced Parkinson’s Disease: DUOGLOBE Final 3-Year Results
por: Chaudhuri, K. Ray, et al.
Publicado: (2023)

Effects of levodopa/carbidopa intestinal gel versus oral levodopa/carbidopa on B vitamin levels and neuropathy
por: Loens, Sebastian, et al.
Publicado: (2017)

Problems related to levodopa‐carbidopa intestinal gel treatment in advanced Parkinson's disease
por: Udd, Marianne, et al.
Publicado: (2017)

Multicenter study of levodopa carbidopa intestinal gel in Parkinson’s disease: the Turkish experience
por: GÜLTEKİN, Murat, et al.
Publicado: (2020)

Patient and caregiver outcomes with levodopa-carbidopa intestinal gel in advanced Parkinson’s disease
por: Valldeoriola, Francesc, et al.
Publicado: (2021)

DUOGLOBE: One‐Year Outcomes in a Real‐World Study of Levodopa Carbidopa Intestinal Gel for Parkinson's Disease
por: Standaert, David G., et al.
Publicado: (2021)

Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease: A Systematic Review and Meta-Analysis
por: Wang, Libo, et al.
Publicado: (2018)

Comprehensive assessment of levodopa-carbidopa intestinal gel for Turkish advanced Parkinson’s disease patients
por: SÜCÜLLÜ KARADAĞ, Yeşim, et al.
Publicado: (2021)

The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson’s Disease in England
por: Chaudhuri, K. Ray, et al.
Publicado: (2022)

Levodopa‐Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson's Disease in a Randomized Trial
por: Freire‐Alvarez, Eric, et al.
Publicado: (2021)

Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets
por: Othman, Ahmed A, et al.
Publicado: (2014)

The Advantages of Levodopa-Carbidopa Intestinal Gel for Patients with Advanced Parkinson’s Disease: A Systematic Review
por: Zhang, Xing-Ru, et al.
Publicado: (2020)

Levodopa-Carbidopa Intestinal Gel may improve treatment-resistant freezing of gait in Parkinson’s disease
por: Shackleford, Melanie R., et al.
Publicado: (2022)

Levodopa–carbidopa intestinal gel in advanced Parkinson’s disease: long-term results from COSMOS
por: Fasano, Alfonso, et al.
Publicado: (2023)

Proposition of zinc supplementation during levodopa–carbidopa intestinal gel treatment
por: Matsuyama, Hirofumi, et al.
Publicado: (2018)

Long‐term safety and effectiveness of levodopa‐carbidopa intestinal gel infusion
por: De Fabregues, Oriol, et al.
Publicado: (2017)

Initial Experience of the Levodopa–Entacapone–Carbidopa Intestinal Gel in Clinical Practice
por: Öthman, Mezin, et al.
Publicado: (2021)

Tolcapone improves outcomes in patients with Parkinson disease treated by levodopa/carbidopa intestinal gel: A pilot study
por: Valkovič, Peter, et al.
Publicado: (2022)

24-hour levodopa-carbidopa intestinal gel may reduce troublesome dyskinesia in advanced Parkinson’s disease
por: Cruse, Belinda, et al.
Publicado: (2018)

Parkinson’s Kinetigraph in the Selection of Levodopa-Carbidopa Intestinal Gel for Motor Fluctuations Refractory to Deep Brain Stimulation
por: Noui, Yassine, et al.
Publicado: (2021)

Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety
por: Poewe, Werner, et al.
Publicado: (2019)

Rescue Levodopa/Carbidopa Intestinal Gel for Secondary Deep Brain Stimulation Failure
por: Bautista, Juan Miguel Pilar, et al.
Publicado: (2020)

24-Hour Levodopa-Carbidopa Intestinal Gel: Clinical Experience and Practical Recommendations
por: Thakkar, Sandeep, et al.
Publicado: (2021)

Apraxia of eyelid opening might be critical for levodopa-carbidopa intestinal gel treatment
por: Kataoka, Hiroshi, et al.
Publicado: (2020)

Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson’s Disease in the United States
por: Amjad, Fahd, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2l8iq78rsmppieh09s1lgclabg